A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis
What it found
We found no results in the registry or in papers.
This trial finished 15 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- Mitoxantrone
What it measured
Main measures
Multiple Sclerosis Impact Scale (MSIS) and Expanded Disability Status Scale (EDSS)
Disability progressionQuality of life (reported by participants)
Other measures (1)
Not provided at time of registration
Who could take part
Relapsing MS · 18 and over
Inclusion: 1. Definite MS as determined by the McDonald criteria (Ann Neurol, July 2001) with a relapsing remitting disease course. 2. Aged 18 to 55. 3. 2 relapses in the past 2 years (this is part of the ABN guidelines to use GA and Interferon). 4. EDSS 0 - 5.5 (able to walk at least 100m without aid). 5. Disease duration less than 5 years from onset (if used later in the disease may not prevent progression). 6. At least 3 of the following: patients with three or more attacks in the first two years of disease; motor involvement in early attacks (weakness/ataxia); incomplete recovery from early attacks (EDSS >1.5); 10 or more T2 weighted MRI brain lesions (these 4 items are markers of increased risk of early disability). Exclusion: Not provided at time of registration
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Not provided at time of registration
Loading reviews and guidelines…
Related trials
History
Started
Feb 2005
Finished
Dec 2010
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error